Carlsmed has announced that the Centre for Medicare and Medicaid Services (CMS) has granted its aprevo personalised interbody devices a transitional pass-through (TPT) payment as part of the quarterly update of the 2021 Medicare Hospital Outpatient Prospective Payment System.
The pass-through payment provides outpatient facilities with an incremental Medicare payment for procedures in which aprevo is used.
Mike Cordonnier, CEO of Carlsmed, said: “FDA granted the aprevo personalised interbody devices breakthrough device designation in 2020 based on the device’ss potential to provide a more effective treatment when compared to existing treatment options.
“Having both New Technology Add-on Payment (NTAP) and TPT enhanced reimbursement now provides patients access to new technology for inpatient and outpatient spine surgery procedures.”
The aprevo NTAP and TPT payment reimbursement programs took effect on October 1, 2021.
